Available today
FDA-cleared PSWT device
ActiPatch® is a commercial device for its labeled pain use. This is the current product foundation.
Current productsAI-assisted research
Discovery R&D,
built AI-native.
Electrome connects scientific evidence, AI-assisted research, signal modeling, protocol design, controlled experiments, statistical validation, and documentation in one human-led learning loop.
Research workflow
01EvidenceGround the question
02ComputeRank and model
03ExperimentTest in the lab
04ValidateReplicate and review
05DocumentPublish or stop
One platform, two realities
A commercial foundation. A research engine.
Pain is Electrome's first commercial focus. FDA-cleared devices establish a real operating foundation while Discovery R&D investigates what bioelectric medicine could become.
Research platform
MATRIX Discovery
Operating internal AI-native R&D software for evidence, candidate ranking, modeling, controlled laboratory experiments, replication, publication, and documentation, all under a human scientific release gate.
Explore the scienceDiscovery R&D pipeline
From a research question to evidence that can stand up to review.
- Commercial todayFDA-cleared PSWT devices for labeled pain uses
- Operating internallyLaboratory research software and workflows, not patient care
- Research directionProposed concept, not built, cleared, or available
- 1Evidence · source-grounded literature review (Steps 01-03)
- 2Computation · hypotheses and mathematical models (Steps 04-05)
- 3Controlled lab · protocol and wet-lab signal delivery (Steps 06-07)
- 4Measurement · instrument observations, statistics, replication (Step 08)
- Scientist review sits between every phase; reviewed results return to the question and the models.
Phase 1 · Question and evidence
AI-native, scientist-directed
01Define the research question
Scientists set a bounded biological question, success criteria, and interpretation limits.
Operating internally02Discover the literature
Specialized research agents search and organize public scientific evidence for review.
Operating internally03Extract and rank evidence
Evidence is grounded to sources, compared for quality, and ranked without replacing scientific judgment.
Operating internally
Human review: Scientists review grounded evidence before hypotheses
Phase 2 · Hypotheses and models
AI-native, scientist-directed
04Generate and challenge hypotheses
Agents work adaptively in parallel and sequence to propose, compare, and challenge candidate explanations.
Operating internally05Model candidate signals
Mathematical and statistical models help scientists explore candidate signal-response relationships.
Operating internally
Human review: Scientists select candidates before any protocol
Phase 3 · Controlled laboratory work
Researcher-run
06Design a controlled protocol
Scientists translate selected candidates into reproducible laboratory protocols and review gates.
Operating internally07Run hardware-controlled experiments
Defined signals are delivered in controlled wet-lab studies; instruments record experimental observations.
Operating internally08Validate and replicate
Researchers apply statistical checks, replication, negative controls, and human interpretation.
Operating internally
Human review: Scientists approve protocols and interpret every experiment
Human scientific release gate
After review
09Publish and document
Results that clear scientific review can advance to peer review, publication, and regulatory documentation.
Operating internally10Expand the learning loop
The roadmap links validated evidence back into improved models and future programmable delivery research.
In development
Work that does not clear review stops or returns to an earlier phase. Nothing here reaches a patient.
Learning loop: reviewed results, including negative ones, return to step 01 to sharpen the next research question and to step 05 to refine candidate models. Each return passes human review again.
Specialized AI tools support the research workflow.
MATRIX Discovery supports research under human scientific oversight and is not an autonomous scientist. It does not diagnose, monitor, or treat a person.
Evidence grounding
AI-assisted tools help search, extract, compare, and rank scientific evidence while preserving links to source material.
Research workflow support
Specialized AI tools can support parallel and sequential research tasks as scientists direct the workflow.
Modeling and simulation
Mathematical and statistical models help scientists compare candidate signal-response relationships before experiments.
Human scientific review
Scientists define the question, inspect assumptions, operate experiments, interpret findings, and decide what advances.
Maturity map
Clear about what exists and what does not yet.
| Capability | Commercial today | Operating internally | In development | Research direction |
|---|---|---|---|---|
| FDA-cleared PSWT devices for labeled pain uses | Commercial today | |||
| MATRIX Discovery internal R&D software | Operating internally | |||
| AI-assisted evidence, candidate ranking, and protocol work | Operating internally | |||
| Controlled wet-lab experimentation and statistical review | Operating internally | |||
| Expanded research programs | In development | |||
| Stronger model-to-experiment feedback | In development | |||
| Additional validation and documentation workflows | In development | |||
| MATRIX System mat research and bench prototyping | In development | |||
| Proposed Scan → Diagnose → Compute loop | Research direction | |||
| Human-authorized Treat → Measure → Adapt | Research direction | |||
| Treat again only after review | Research direction |
Validation and an appropriate regulatory pathway are required before any future MATRIX System use. A row's position is a current status, not a timeline.
First end-to-end proof point
A pipeline-selected candidate reached peer review.
A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work.
This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.
Frontiers in Medicine · August 11, 2026Preclinical · In vitro · Research only
Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitro
Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers
Division of Immunology at the Tulane National Biomedical Research Center, Tulane University
First official pathway · Company program milestone
- 01AI-native evidence analysis and hypotheses
Specialized AI tools supported literature review and hypothesis work.
- 02Modeling and candidate ranking
Models helped rank a candidate for scientists to consider.
- 03Human scientific review
Scientists decided what advanced to the laboratory.
- 04Controlled laboratory research
In-vitro experiments with replication, run by researchers.
- 05Peer-reviewed publication
Frontiers in Medicine, August 2026.
Current stagePreclinical · In vitro · Research onlyNo clinical or human studies are shown here.
Lyme research is the first official pathway Electrome reports as having progressed through MATRIX Discovery to peer review. This is a company program milestone, not independent validation that AI tools caused the result. A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work.
This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition.
Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitroMATRIX Discovery and GrowthOS serve different purposes.
MATRIX Discovery is internal R&D software supporting therapeutic research. GrowthOS is Electrome's separate internal, human-governed commercialization and operating infrastructure. It coordinates company work; it is not a patient-care or scientific decision-making system.